Advertisement

Advertisement

DE:PCJ Stock Latest News

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

The FlyAbeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

Abeona Therapeutics price target raised to $30 from $28 at Cantor Fitzgerald

PremiumThe Fly

Abeona Therapeutics price target raised to $30 from $28 at Cantor Fitzgerald

14d ago

Abeona Therapeutics initiated with a Buy at Roth Capital

PremiumThe Fly

Abeona Therapeutics initiated with a Buy at Roth Capital

15d ago

Abeona activates UF Health as qualified treatment center for Zevaskyn

PremiumThe Fly

Abeona activates UF Health as qualified treatment center for Zevaskyn

16d ago

Abeona Therapeutics Updates Investor Presentation at Conference

PremiumCompany Announcements

Abeona Therapeutics Updates Investor Presentation at Conference

16d ago

Abeona Therapeutics Earnings Call Highlights ZEVASKYN Ramp

PremiumCompany AnnouncementsAbeona Therapeutics Earnings Call Highlights ZEVASKYN Ramp

1M ago

Abeona Buy Rating Reaffirmed as Commercial Momentum Builds and $20 Price Target Remains Unchanged

Ratings

Abeona Buy Rating Reaffirmed as Commercial Momentum Builds and $20 Price Target Remains Unchanged

1M ago

Abeona Therapeutics reports Q2 EPS (35c), consensus (25c)

The Fly

Abeona Therapeutics reports Q2 EPS (35c), consensus (25c)

2M ago

Abeona Therapeutics price target lowered to $21 from $22 at Oppenheimer

PremiumThe Fly

Abeona Therapeutics price target lowered to $21 from $22 at Oppenheimer

2M ago

Abeona Therapeutics price target lowered to $15 from $20 at Alliance Global

PremiumThe Fly

Abeona Therapeutics price target lowered to $15 from $20 at Alliance Global

2M ago

ABEO Earnings this Week: How Will it Perform?

PremiumPre-Earnings

ABEO Earnings this Week: How Will it Perform?

2M ago

Abeona Therapeutics: CMS Reimbursement Catalyst Supports ZEVASKYN Uptake and Unchanged $20 Price Target

PremiumRatings

Abeona Therapeutics: CMS Reimbursement Catalyst Supports ZEVASKYN Uptake and Unchanged $20 Price Target

2M ago

Abeona Therapeutics activates Cincinnati Children’s as treatment center

PremiumThe FlyAbeona Therapeutics activates Cincinnati Children’s as treatment center

2M ago

Abeona Shareholders Back Board, Equity Plan at Meeting

Company Announcements

Abeona Shareholders Back Board, Equity Plan at Meeting

4M ago

Abeona Therapeutics announces resignation of board member

Company Announcements

Abeona Therapeutics announces resignation of board member

4M ago

Abeona Therapeutics Updates Investor Presentation Under Regulation FD

PremiumCompany Announcements

Abeona Therapeutics Updates Investor Presentation Under Regulation FD

4M ago

Abeona Advances ABO-701 T-Cell Therapy Toward IND

PremiumCompany Announcements

Abeona Advances ABO-701 T-Cell Therapy Toward IND

4M ago

Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum

PremiumCompany Announcements

Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum

4M ago

Abeona Therapeutics Signals Strong Early ZEVASKYN Launch

PremiumCompany Announcements

Abeona Therapeutics Signals Strong Early ZEVASKYN Launch

5M ago

Abeona Therapeutics reports Q1 EPS (30c), consensus (39c)

PremiumThe FlyAbeona Therapeutics reports Q1 EPS (30c), consensus (39c)

5M ago

ABEO Upcoming Earnings Report: What to Expect?

Pre-Earnings

ABEO Upcoming Earnings Report: What to Expect?

5M ago

Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair

Company Announcements

Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >